These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 33602617)

  • 1. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
    Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
    J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.
    Chaidez A; Pan Z; Sundaram SS; Boster J; Lovell M; Sokol RJ; Mack CL
    Hepatol Commun; 2022 Nov; 6(11):3015-3023. PubMed ID: 36069338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
    Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
    AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan.
    Roulot D; Roudot-Thoraval F; NKontchou G; Kouacou N; Costes JL; Elourimi G; Le Clesiau H; Ziol M; Beaugrand M
    Liver Int; 2017 Dec; 37(12):1897-1906. PubMed ID: 28556413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
    Lavynenko O; Abdul-Ghani M; Alatrach M; Puckett C; Adams J; Abdelgani S; Alkhouri N; Triplitt C; Clarke GD; Vasquez JA; Li J; Cersosimo E; Gastaldelli A; DeFronzo RA
    Diabetes Obes Metab; 2022 May; 24(5):899-907. PubMed ID: 35014145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
    Lee JI; Lee HW; Lee KS
    World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis.
    Karlas T; Petroff D; Feisthammel J; Beer S; Blüher M; Schütz T; Lichtinghagen R; Hoffmeister A; Wiegand J
    Obes Surg; 2022 Aug; 32(8):2495-2503. PubMed ID: 35713854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
    Wan T; Köhn N; Kröll D; Berzigotti A
    Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
    Ciardullo S; Perseghin G
    Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.